SCHEMBL2496483

SCHEMBL2496483

Nc1nc(Nc2ccc3cc[nH]c3c2)ncc1-c1n[nH]c2ccc(F)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.51
EGFR P00533 3/20 0.39
CDC7 O00311 2/20 0.39
MAPKAPK2 P49137 1/20 0.39
ESR1 P03372 1/20 0.38
AHR P35869 1/20 0.38
ULK1 O75385 1/20 0.38
LRRK2 Q5S007 2/20 0.37
PLK2 Q9NYY3 2/20 0.37
NEK2 P51955 1/20 0.37
NEK5 Q6P3R8 1/20 0.37
NEK1 Q96PY6 1/20 0.37
IGF1R P08069 1/20 0.37
KDR P35968 1/20 0.37
WEE1 P30291 1/20 0.37
LCK P06239 1/20 0.37
KIT P10721 1/20 0.37
FGFR3 P22607 1/20 0.37
FLT3 P36888 1/20 0.37
PLK1 P53350 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2494409 0.82 PLK2 (0.44) SYKEGFRMAPKAPK2PLK2KDR
SCHEMBL14633733 0.80 PTGS2 (0.49)
SCHEMBL14633488 0.80 GRM4 (0.49)
SCHEMBL2468759 0.79 NTRK1 (0.44) SYKEGFRKDRLCKKIT
SCHEMBL14633987 0.78 NTRK1 (0.37) LRRK2PLK2NEK2NEK5NEK1
SCHEMBL2467117 0.78 KDR (0.51) SYKEGFRIGF1RKDRLCK
SCHEMBL14634034 0.78 EPHB4 (0.49) SYKLRRK2KDRLCKFLT3
SCHEMBL2471278 0.78 RIPK2 (0.43) PLK2NEK2NEK5NEK1LCK
SCHEMBL14634292 0.77 RIPK2 (0.44)
SCHEMBL14634186 0.77 RIPK2 (0.41) SYKEGFRKDRLCKKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed
WO-2011120025-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 SYK 409/4885EGFR 382/4885CDC7 210/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 SYK 449/4885EGFR 563/4885CDC7 251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.